Ablynx awarded €2.1m to develop nanobody treatment for eye disease
29 August 2014
Ghent-based Ablynx has been awarded a €2.1 million grant by the
Flemish Agency for Innovation by Science and Technology (IWT) to
develop the use of nanobodies for a novel approach to the treatment
of diseases of the eye.
The grant is available over a period of three years and will
allow the development and subsequent testing of Nanobody leads in
relevant pre-clinical disease models.
Dr Tony De Fougerolles, CSO of Ablynx, commented: "This grant is
a further clear endorsement of the innovative potential of the
Nanobody platform and its ability to generate differentiated drugs
in disease areas which are scientifically challenging and which
represent a high unmet medical need. Ophthalmology is an
increasingly important area for many pharmaceutical companies as
they seek to meet the demands of an ageing population. We are very
grateful for the continued commitment by IWT to support world-class
science in Belgium."
Nanobodies, are a novel class of therapeutic proteins, first
discovered in camels and llamas, based on single-domain antibody
fragments and with applications for a range of serious human
diseases, including inflammation, haematology, oncology and